A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia
NCT07734493
This study is recruiting at 10 US sites in 7 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this clinical trial is to learn whether the investigational drug LTX-001 is safe and well tolerated in adults with a diagnosis of schizophrenia who are having a recent worsening of their symptoms (an acute exacerbation).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Schizophrenia
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Leal Therapeutics, Inc
- Last updated on ClinicalTrials.gov
- September 17, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arkansas · 1
- Pillar Clinical Research, LLC · Little Rock, AR
California · 1
- Collaborative Neuroscience Research, LLC · Los Alamitos, CA
Florida · 4
- University Clinical Research-DeLand, LLC d/b/a Accel Research Sites - DeLand Clinical Research Unit · DeLand, FL
- Behavioral Clinical Research, Inc. · Hollywood, FL
- CenExel Hollywood FL · Hollywood, FL
- Innovative Clinical Research, Inc. · Miami Lakes, FL
Georgia · 1
- CenExel iResearch, LLC · Decatur, GA
Maryland · 1
- CBH Health LLC., dba CenExel Gaithersburg MD · Gaithersburg, MD
New Jersey · 1
- Hassman Research Institute, LLC · Marlton, NJ
Texas · 1
- Pillar Clinical Research, LLC · Richardson, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.